The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
A risk-based aftercare and regular screening for asymptomatic metastatic disease with molecular markers in the absence of any radiological findings can potentially revolutionize current follow-up care of breast cancer survivors and enable potential treatment even before patients suffer from symptomatic, incurable disease.
Authors
- Sophia Huesmann
- Lisa Wiesmüller (ORCID: https://orcid.org/0000-0002-2397-5041)
- Franziska Mergel
- Brigitte Rack (ORCID: https://orcid.org/0000-0002-7539-4839)
- Andreas Hartkopf
- Sabine Heublein (ORCID: https://orcid.org/0000-0002-5326-0186)
- Thomas W. P. Friedl (ORCID: https://orcid.org/0000-0002-4773-8067)
- Klaus Pantel (ORCID: https://orcid.org/0000-0001-5736-2772)
- Henning Schäffler
- Forca Mehmeti
- Kerstin Pfister (ORCID: https://orcid.org/0009-0002-2831-1401)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-1709-1079)
- Angelina Fink (ORCID: https://orcid.org/0000-0002-9481-830X)
- Wolfgang Janni
- Tatjana Braun
Institutions
- Universität Hamburg (DE)
- Universitätsklinikum Erlangen (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- University Children's Hospital Tübingen (DE)
- University Hospital Ulm (DE)
- SLK-Kliniken Heilbronn (DE)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1371/journal.pone.0331203
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- European Federation of Pharmaceutical Industries and Associations
- Bundesministerium für Bildung und Forschung
- Daiichi-Sankyo
- Eisai